Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy:…

By C. Osborne, J. Pippen, S. Jones, L. Parker, M. Ellis, S. Come, Stan Gertler, J. May, Gary V. Burton, I. Dimery and 4 more. Journal of Clinical Oncology, 2002

636 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/154166a59df4eec33792620efb2165faeb487592

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Lichinitser
2. R. Torres
3. J. Lindemann
4. R. Khasanov
5. Miguel Martín
6. I. Smirnova
7. L. Petruželka
8. F. Sapunar

Citations in the corpus

• Mechanisms of tamoxifen resistance. (2004, neutral): “In fact up to 20% of patients who have relapsed on tamoxifen respond to aromatase inhibitors or to the ER-down-regulator fulves-trant suggesting that the ER continues to regulate growth even in many tamoxifen-resistant patients (Howell et al. 2002, Osborne et al. 2002).”
• Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. (2010, background): “treatments have similar efficacy and an acceptable safety profile with a low incidence of withdrawals.(4,5) These results led to the registration of fulvestrant 250”